MicroRNA signatures in hereditary breast cancer

• Published in: Breast cancer research and treatment 2013-11, Vol.142 (1), p.19-30
• Main Authors: Murria Estal, Rosa, Palanca Suela, Sarai, de Juan Jiménez, Inmaculada, Egoavil Rojas, Cecilia, García-Casado, Zaida, Juan Fita, María José, Sánchez Heras, Ana Beatriz, Segura Huerta, Ángel, Chirivella González, Isabel, Sánchez-Izquierdo, Dolors, Llop García, Marta, Barragán González, Eva, Bolufer Gilabert, Pascual
• Format: Article
• Language: English
• Subjects: Adult; Analysis; Biological and medical sciences; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; BRCA1 Protein - genetics; BRCA1 Protein - metabolism; BRCA2 Protein - genetics; BRCA2 Protein - metabolism; Breast cancer; Breast Neoplasms - congenital; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cancer; Cancer research; Cancer therapies; Cluster Analysis; Female; Formaldehyde; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene mutations; Genes; Genetic aspects; Genetic disorders; Genetic markers; Gynecology. Andrology. Obstetrics; Humans; Immunohistochemistry; Mammary gland diseases; Medical sciences; Medicine; Medicine & Public Health; Methylation; MicroRNA; MicroRNAs; MicroRNAs - genetics; Middle Aged; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Mutation; Oncology; Preclinical Study; Reproducibility of Results; Transcriptome; Tumors
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/s10549-013-2723-7

This study aims to identify signatures of miR associated with hereditary, BRCA1 or BRCA2 mutation positive breast cancer (BC), and non-hereditary BC, either sporadic (SBC) or non-informative (BRCAX). Moreover, we search for signatures associated with tumor stage, immunohistochemistry and tumor molecular profile. Twenty formalin fixed paraffin embedded (FFPE) BCs, BRCA1, BRCA2, BRCAX and SBC, five per group were studied. Affymetrix platform miRNA v.3.0 was used to perform miR expression analysis. ER, PR, HER2 and Ki67 protein expression was analyzed by immunohistochemistry. BRCA1 , BRCA2 and RASSF1 methylation analysis, AURKA copy number variations, and BRCA1 and BRCA2 deletions, were studied by MLPA. We validated eight of the miR selected by the arrays in 77 BCs by qRT-PCR. The miR profiles associated with tumor features were studied applying the Sparse Partial Least Squares Discriminant Analysis . MiR discrimination capability to distinguish hereditary and non-hereditary BC was analyzed by the discriminant function. With 15 out of 1,733 hsa-miRs, it was possible to differentiate the four groups. BRCA1, BRCA2 and SBC were associated with clusters of hyper-expressed miRs, and BRCAX with hypo-expressed miRs. Hsa-miR-4417 and hsa-miR-423-3p expressions (included among the eight validated miRs) differentiated 70.1 % of hereditary and non-hereditary BCs. We found miR profiles associated with tumor features like node involvement, histological grade, ER, PR and HER2 expression. Regarding molecular parameters, we only found a weak association of miRs in BC harboring losses in AURKA . We conclude that array miR expression profiles can differentiate the four study groups using FFPE BC. However, miRs expression estimated by qRT-PCR differentiates only hereditary and non-inherited BCs. The miR expression array is a simple and rapid approach that could be useful to facilitate the identification of those SBC carrying genetic or epigenetic changes in BRCA genes responsible of BRCA-like phenotype. These patients could benefit from the treatment with PARP inhibitors.